Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross, M.D., will participate in the “Novel Immuno-Oncology” panel at Cowen’s 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross, M.D., will participate in the “Novel Immuno-Oncology” panel at Cowen’s 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET. The discussion will be accessible via a live webcast on the company's website, with an archived replay available for 30 days post-conference. Surface Oncology is focused on developing next-generation therapies targeting the tumor microenvironment, including clinical-stage programs and collaborations with major pharmaceutical companies.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was +1.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion at Cowen’s 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.
A live webcast of the panel discussion will be accessible from the Events & Presentations page of the company's website. A subsequent archived replay of the session will be available on the website for 30 days following the end of the conference.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562; IND filed). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.